Physician

Rakesh Rohatgi, M.D.

According to 2025 Medicare claims, Rakesh Rohatgi, M.D. (NPI: 1750383980) practices hematology/oncology in the Orlando-Kissimmee-Sanford, FL market, with the plurality of this provider's patient population coming from Lake, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 32159-6823.

Rohatgi's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,448 traditional Medicare patients, billed 520,701 HCPCS/CPT codes, and received $5,417,400 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,221 prescription claims across 482 beneficiaries totaling $6,589,178 in drug costs, led by Revlimid (Lenalidomide). DME data shows 51 claims. Open Payments data shows 173 records totaling $4,982. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have risen steadily, from $2,551,897 to $6,589,178. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $12,630 to $0.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,307	383,621	$3,321,114
2016	1,517	605,073	$5,007,441
2017	1,442	603,802	$5,472,604
2018	1,391	922,622	$6,222,098
2019	1,328	802,958	$5,677,101
2020	1,272	783,726	$5,717,683
2021	1,437	742,378	$4,983,014
2022	1,317	670,057	$4,916,014
2023	1,451	622,355	$4,712,121
2024	1,448	520,701	$5,417,400

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	410	2,038	$2,551,897
2016	450	2,617	$3,769,674
2017	511	2,853	$3,762,667
2018	501	2,846	$4,915,935
2019	488	2,448	$4,796,394
2020	415	2,305	$5,295,897
2021	476	2,338	$5,066,943
2022	478	2,423	$4,998,342
2023	473	2,164	$4,780,378
2024	482	2,221	$6,589,178

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	13	216	$24,092
2016	17	179	$77,525
2017	N/R	43	$6,458
2018	N/R	97	$10,597
2019	11	55	$7,148
2020	N/R	13	$1,550
2021	N/R	11	$1,302
2022	N/R	12	$1,970
2023	N/R	N/R	N/R
2024	11	51	$4,483

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	948	2,310	$94
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	476	753	$64
96372	Injection of drug or substance under skin or into muscle	421	1,878	$10
36415	Insertion of needle into vein for collection of blood sample	1,089	3,839	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	971	3,692	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	95	2,639	$1,556,470
Jakafi	Ruxolitinib Phosphate	61	1,830	$1,030,495
Venclexta	Venetoclax	46	1,380	$706,107
Imbruvica	Ibrutinib	35	980	$561,411
Calquence	Acalabrutinib Maleate	32	960	$485,580

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
L8000	Breast prosthesis, mastectomy bra, without integrated breast prosthesis form, any size, any type	N	11	13	$2,506
B4152	Enteral formula, nutritionally complete, calorically dense (equal to or greater than 1.5 kcal/ml) with intact nutrients, includes proteins, fats, carbohydrates, vitamins and minerals, may include fiber, administered through an enteral feeding tube, 100 calories = 1 unit	N	N/R	13	$1,366
J8521	Capecitabine, oral, 500 mg	N	N/R	12	$448
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	13	$163

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	173	$4,982	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Rakesh Rohatgi, M.D.?

Tedicare shows public-source Medicare data for Rakesh Rohatgi, M.D. (NPI 1750383980), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Rakesh Rohatgi, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Rakesh Rohatgi, M.D.?

Rakesh Rohatgi, M.D. is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does Rakesh Rohatgi, M.D. have Open Payments data?

Rakesh Rohatgi, M.D. has 173 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.